<DOC>
	<DOCNO>NCT01323140</DOCNO>
	<brief_summary>Watson 's testosterone transdermal system delivers male sex hormone skin treatment men sex hormone insufficiency .</brief_summary>
	<brief_title>Pharmacokinetics , Metabolism , Efficacy , Safety Study Two Testosterone Matrix Transdermal Systems</brief_title>
	<detailed_description>The present study design characterize efficacy safety testosterone Watson 's testosterone matrix transdermal system ( TMTS ) .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male , 18 65 year age ; Documented testosterone deficiency ; BMI 18 33 . Evidence prostate cancer benign prostate hyperplasia ; Taking medication interfere testosterone metabolism ; History alcohol drug substance abuse ; Abnormal ECG ; Allergic transdermal product ; Skin condition interfere transdermal system application assessment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>hypogonadism , testosterone , transdermal system</keyword>
</DOC>